Israeli Defense/BioNTech-Paid Scientist Develop mRNA Jab That Forces the Body to Make Black Death Plague Fragments That Last in the Body 300 Times Longer

While aerosolizing the plague bacterium respiratory form that spreads person-to-person through the air, making the problem and the solution at the same time.

JON FLEETWOOD
NOV 23, 2026 • PAID

71 14 28 Share

Excerpt from the November 2026 *Journal of Controlled Release* study highlighting researchers' experimental use of plague-associated material in a vaccine designed to protect mice against lethal bubonic plague. The paper's cover page appears in the inset.

Researchers at the Israel Institute for Biological Research and Tel Aviv University published a paper on November 19, 2026, in the *Journal of Controlled Release* describing an mRNA vaccine that is said to instruct cells to produce the F1 protein of *Yersinia pestis* (the bacterium that causes plague, including the historical Black Death).

Corresponding author Dan Peer disclosed in the conflict-of-interest statement that he conducts sponsored research at Tel Aviv University for BioNTech SE.

The paper states that fusing the antigen to an Fc fragment "extends systemic antigen bioavailability by over 300-fold."

Peer conducted earlier experiments that aerosolized the plague bacterium in the respiratory form that spreads person-to-person through the air.

Citizens never consented to defense laboratories and a BioNTech-linked scientist engineering plague antigen to remain in the body more than 300 times longer. mRNA from mRNA vaccines has been detected in extracellular vesicles and exosomes, raising unresolved questions about shedding and unintended exposure. No public safety assessment addressed the risks of forcing cells to produce fragments of a Category A bioterrorism agent with dramatically extended persistence. What happens if the aerosolized plague bacterium used in the respiratory challenge experiments escapes containment? Who in the Ministry of Defense authorized dual-use work that could be misused for bioterrorism? Why are these groups creating both the aerosolized plague problem and the mRNA solution at the same time?

Journal Pre-proof

mRNA-LNP vaccine encoding for Fc-scaffold antigen drives FcγR-independent immunity

Shani Benarroch, Hila Cohen, Uri Elia, Yinon Levy, Tal Noy-Porat, Ronit Rosenfeld, David Gur, Ron Alcalay, Maya Shlosberg, Govinda Reddy Kundoor, Yahel Avraham, Meir Goldsmit, Erez Bar-Haim, Inbal Hazan-Halevy, Ofer Cohen, Rony Dahan, Emanuelle Mamroud, Dan Peer

PII: S0168-3659(26)00959-4
DOI: https://doi.org/10.1016/j.jconrel.2026.115555
Reference: COREL 115555
To appear in: *Journal of Controlled Release*
Received date: 10 June 2026
Revised date: 3 November 2026
Accepted date: 17 November 2026

Please cite this article as: S. Benarroch, H. Cohen, U. Elia, et al., mRNA-LNP vaccine encoding for Fc-scaffold antigen drives FcγR-independent immunity, *Journal of Controlled Release* (2026), https://doi.org/10.1016/j.jconrel.2026.115555

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cover page of a November 2026 *Journal of Controlled Release* paper by researchers affiliated with the Israel Institute for Biological Research and Tel Aviv University describing an experimental mRNA vaccine engineered to increase the persistence of a plague-associated antigen. The paper was accepted November 17, 2026.

Donate

Share

- Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood.
- If you value this reporting, consider **upgrading to a paid** subscription.
- For advertising & sponsorship opportunities, contact us by clicking below.

Message Jon Fleetwood

Defense Lab & Industry-Linked Researcher Target Plague Antigen

The Israel Institute for Biological Research in Ness Ziona is a government institute whose stated mission includes countermeasures against biological threats.

Dan Peer of Tel Aviv University's Laboratory of Precision NanoMedicine is listed as corresponding author.

His conflict-of-interest statement names BioNTech SE among the entities for which he conducts sponsored research at the university, receives licensing fees, consults, or lectures.

The paper itself identifies the collaboration between these groups.

Tel Aviv University's official faculty profile identifies Professor Dan Peer of the Shmunis School of Biomedicine and Cancer Research as the corresponding author of the November 2026 plague mRNA vaccine study. Peer's published financial disclosures identify BioNTech SE among companies with which he maintains financial relationships.

Declaration of competing interest

D.P. receives unrelated licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee), or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNTech SE, Earli Inc., Kernal Biologics, LAND Therapeutics, Merck KGaA, New Phase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, Teva Pharmaceuticals Inc. The rest of the authors declare no financial interest.

Conflict-of-interest disclosure from the November 2026 *Journal of Controlled Release* plague mRNA vaccine study identifying BioNTech SE among the companies with which corresponding author Dan Peer has financial relationships, including potential licensing fees, investments, consulting, paid lectures, or sponsored research at Tel Aviv University. The disclosure does not specify which relationship applies to BioNTech.

300-Fold Greater Exposure Through Engineered Persistence

The November 19 paper reports that the Fc-fused F1 antigen produced more than 300-fold greater systemic bioavailability than the non-fused version.

The authors describe this as the result of structural stabilization and prolonged persistence that creates a "sustained kinetic window for immune priming."

pharmacokinetic stabilizer. Through systematic architectural design, variation of Fc isotypes, species-matched scaffolding, and glycosylation profiling, we reveal that Fc-integration extends systemic antigen bioavailability by over 300-fold, providing a sustained kinetic window for immune priming. Remarkably, immunogenicity is preserved in Fcγ receptor (FcγR)-deficient

Excerpt from the November 2026 *Journal of Controlled Release* study in which researchers report that engineering an Fc protein fragment into their experimental plague mRNA vaccine increased systemic antigen bioavailability more than 300-fold, extending the body's exposure to the plague-associated F1 protein.

They Are Aerosolizing the Plague Bacterium Respiratory Form That Spreads Person-to-Person Through the Air

A related 2025 paper from the same collaboration in *Advanced Science* evaluated a bivalent F1/LcrV mRNA construct against pneumonic plague challenge in mice.

In those experiments, the animals were exposed to the bacterium through the respiratory route so researchers could test whether the vaccine protected against the lung form of the disease.

Pneumonic plague is the form that spreads person-to-person through the air.

The same aerosolization methods used for these challenges carry documented risks of accidental release from containment and potential dual-use applications.

That 2025 paper also described construction of an F1⁻ mutant strain of *Yersinia pestis*.

JonFleetwood.com first reported on that paper on July 16, 2025.

RESEARCH ARTICLE

ADVANCED SCIENCE
www.advancedscience.com

Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague

Uri Elia, Yinon Levy, Hila Cohen, Ayelet Zauberman, David Gur, Inbal Hazan-Halevy, Moshe Aftalion, Shani Benarroch, Erez Bar-Haim, Orit Redy-Keisar, Ofer Cohen, Dan Peer, and Emanuelle Mamroud*

Yersinia pestis, the causative agent of plague, remains a significant global health hazard and a potential top-tier biothreat despite modern medical advances. Here, two mRNA constructs encoding different versions of the low-calcium response virulence (LcrV) protective antigen, an essential virulence factor of Y. pestis, are designed and evaluated. Next, the immunogenicity and protective efficacy both independently and in combination is assessed with the previously reported F1-encoding mRNA construct in the well-established mouse model of pneumonic plague. The findings reveal that human Fc-conjugated F1 + LcrV combination mRNA vaccination resulted in significant immune activation and substantial protection against intranasal Y. pestis challenge. Notably, the combined vaccine demonstrates protective efficacy against two highly virulent wild-type Y. pestis strains representing distinct biovars and an atypical, unencapsulated strain. This study represents the first comprehensive evaluation of mRNA constructs encoding innovatively designed versions of LcrV and F1 for pneumonic plague prevention, addressing critical gaps in current vaccination approaches. This study establishes the mRNA-lipid nanoparticle (LNP) platform as a promising tool for addressing bacterial pathogens, including those resistant to antibiotics. By broadening its applicability to diverse threats, this technology represents an innovative approach to tackling some of the most pressing challenges in global health.

1. Introduction

Plague, caused by the Gram-negative bacterium *Yersinia pestis*, has been one of the most devastating diseases throughout human history, responsible for three major pandemics including the catastrophic Black Death in the Middle Ages.[1] Although modern medicine has largely contained plague through antibiotics and stringent public health measures, the threat of antibiotic-resistant strains makes it even more important to develop alternative preventive and therapeutic approaches. Recent outbreaks, such as the one in Madagascar in 2017, underscore that plague is not just a disease of the past but continues to pose a significant threat today. The high mortality rates and potential for person-to-person transmission classify *Y. pestis* as a top-tier biothreat, emphasizing the need for effective and quickly producible vaccines to prevent both natural and deliberate outbreaks of pneumonic plague, which can lead to rapid respiratory failure and death if not treated promptly.[2–5]

As of now, there are no licensed vaccines available for *Y. pestis* in Western countries.[6]

U. Elia, Y. Levy, H. Cohen, A. Zauberman, D. Gur, M. Aftalion, E. Bar-Haim, O. Cohen, E. Mamroud
Department of Biochemistry and Molecular Genetics
Israel Institute for Biological Research
Ness-Ziona 76100, Israel

I. Hazan-Halevy, S. Benarroch, D. Peer
Laboratory of Precision NanoMedicine
Shmunis School for Biomedicine and Cancer Research
George S. Wise Faculty of Life Sciences
Tel Aviv University
Tel Aviv 69978, Israel
E-mail: peer@tauex.tau.ac.il

The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/advs.202501286

© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1002/advs.202501286

I. Hazan-Halevy, S. Benarroch, D. Peer
Center for Nanoscience and Nanotechnology
Tel Aviv University
Tel Aviv 69978, Israel

I. Hazan-Halevy, S. Benarroch, D. Peer
Department of Materials Sciences and Engineering
Iby and Aladar Fleischman Faculty of Engineering
Tel Aviv University
Tel Aviv 69978, Israel

I. Hazan-Halevy, S. Benarroch, D. Peer
Cancer Biology Research Center
Tel Aviv University
Tel Aviv 69978, Israel

O. Redy-Keisar
Department of Organic Chemistry
Israel Institute for Biological Research
Ness-Ziona 76100, Israel

Adv. Sci. 2025, 12, 2501286 2501286 (1 of 15) © 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH

Cover page of a 2025 *Advanced Science* study by researchers at the Israel Institute for Biological Research and Tel Aviv University describing an experimental mRNA vaccine tested against pneumonic plague through intranasal exposure of mice to *Yersinia pestis*, the bacterium associated with the Black Death.

Bottom Line

National security and dual-use questions remain open.

Yersinia pestis is a recognized biodefense priority precisely because the pneumonic form spreads person-to-person through the air and has been studied as a potential biological weapon.

Engineering an mRNA platform that forces the body to produce its antigens at more than 300-fold greater total exposure creates a dual-use knowledge base that could be turned toward other ends intentionally or accidentally.

Aerosol challenge experiments with the live bacterium inside a Ministry of Defense-linked laboratory raise immediate questions about containment failure, accidental release, and the absence of any public informed consent process for work this close to a Category A agent.

Donate

Share

- Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood.
- If you value this reporting, consider **upgrading to a paid** subscription.
- For advertising & sponsorship opportunities, contact us by clicking below.

Message Jon Fleetwood

NIH Pays East Carolina University to Mutate Plague Bacteria: 'One of the Deadliest Pathogens Known to Man'
JON FLEETWOOD • OCT 29
Read full story →

HHS Funds Chimeric Bird Flu Pandemic Vaccine Made with Engineered Plague Derivative BECC470s: Journal 'mSphere'
JON FLEETWOOD • AUG 13
Read full story →

U.S. Gov't Deployed Plague-Linked Raccoonpox Vaccines Before 2009 and 2020 Pandemics, Plans More in 2027
JON FLEETWOOD • OCT 7
Read full story →

After U.S. Military 'Genetically Engineers' Plague DNA Into E. Coli Bacteria, WHO Adds Black Death to New Pandemic Watchlist, Raising 'Bioweapon' Concerns: Journal 'Access Microbiology'
JON FLEETWOOD • AUGUST 14, 2024
Read full story →

Israel Engineers Mutant Plague—Puts Its Genes in mRNA Shot That Makes Human Cells Produce Virulence and Immune-Evasion 'Black Death' Proteins: Journal 'Advanced Science'
JON FLEETWOOD • JULY 16, 2025
Read full story →

71 Likes • 28 Restacks

71 14 28 Share

← Previous Next →

Discussion about this post

Comments Restacks

Write a comment...

Autumn Autumn 2d
COVID was also shed person to person by breath...so it was airborne too. Vaxxed people shed even worse... And I believe they're shedding more than just the virus!!
LIKE (4) REPLY SHARE

Jeff 2d
And they make billions doing it. What the science on HIV being man-made? Wonder how much fauci is pulling in from his pharma patents?
LIKE (3) REPLY SHARE

12 more comments...

Top Latest Discussions

Drones Spray 'Self-Spreading' COVID-19 Vaccine for 'Large-Area Inoculation of Humans' in 'DEFUSE' EcoHealth/DARPA Project
Was the COVID-19 pandemic a premeditated operation involving aerosolized bioweapons deployed on unsuspecting populations?
DEC 24, 2024 • JON FLEETWOOD

Military Shuts Down Bill Gates Genetically Modified Mosquito Project in West Africa
Local villages complained that they had "not been sufficiently informed or consulted before the experiments took place."
SEP 12, 2025 • JON FLEETWOOD

Ex-U.S. Air Force Officer Exposes Government's Weather Modification and Chemtrail Activities (Video)
"I realized it was actually coming right out of my office as I was one of the people that was approving the chemicals," Kristen Meghan recounts.
JUL 9, 2024 • JON FLEETWOOD

Biden Admin Accused of 'Murder,' 'Treason,' 'Genocide,' and Use of 'Weapons of Mass Destruction' with COVID-19 Shots, 5G, Chemtrails...
Plaintiffs claim to have been "targeted with biological and technological weapons of mass destruction."
OCT 22, 2024 • JON FLEETWOOD

Rand Paul Introduces Federal Bill to Strip Vaccine Manufacturers of Nationwide Liability Immunity
S.3853 targets the 1986 legal framework that rerouted vaccine injury claims into a federal compensation system.
FEB 14 • JON FLEETWOOD

Pfizer-Type Lipid Nanoparticles Even Containing No mRNA Increase Metastatic Tumor Burden More Than 10-Fold in Mice With Cancer: Journal...
"We demonstrate that LNP administration promotes tumor metastasis by inducing a systemic inflammatory response," study authors confirm. "LNPs...
SEP 2 • JON FLEETWOOD

German Court Orders BioNTech to Hand Over 32 Internal Safety, Toxicity, and Manufacturing Records on 'Comirnaty' COVID-19 mRNA Vaccine
Court affirms injured patients' right to access manufacturer data, forcing disclosure.
APR 15 • JON FLEETWOOD

Ebola Vaccine That 'Sheds' in 31% of Vaccinated Given to Colorado Healthcare Workers Just Down the Road from New Bat Lab
Pending pandemic?
JAN 16, 2024 • JON FLEETWOOD

Israeli-U.S. Geoengineering Company 'Stardust' to Begin Blocking the Sun with Airborne Chemicals 'As Soon as April'
Company will not disclose what the aerosol is made of, raising informed consent worries.
OCT 25, 2025 • JON FLEETWOOD

USDA Drops Live Virus-Containing Rabies Edibles from Helicopters, Airplanes Across United States—'Leaving Persons at Risk for Vaccine...
Lab-engineered "Frankenstein" virus makes animals contagious for weeks, putting humans at risk and raising informed consent concerns.
OCT 16, 2025 • JON FLEETWOOD

See all →

© 2026 Jon Fleetwood · Privacy · Terms · Collection notice

Start your Substack Get the app

Substack is the home for writing, podcasting, and media founders.